Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPFG7H)

Drug Name

JNJ-16269110 Drug Info

Synonyms

SCHEMBL803531; CHEMBL2103860

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Microsomal triglyceride transfer protein (MTTP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-201038	DMQTAGO	Familial hypercholesterolemia	5C80.00	Approved	[2]
SLx-4090	DMM3AI8	Diabetic complication	5A2Y	Phase 2	[3]
Granotapide	DMMZQ7V	Hyperlipidaemia	5C80	Phase 2	[4]
Implitapide	DMTN16K	Hyperlipidaemia	5C80	Phase 2	[5]
KD020	DMZ416B	Kidney disease	GC2Z	Phase 1/2	[6]
GR-328713	DMUANK9	Arteriosclerosis	BD40	Discontinued in Phase 1	[7]
DIRLOTAPIDE	DM2MV9O	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Microsomal triglyceride transfer protein (MTTP)	TTUS1RD	MTP_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00672386) A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
2	Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8.
3	A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85.
4	JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther. 2011 Mar;336(3):850-6.
5	Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan;11(1):67-70.
6	Clinical pipeline report, company report or official report of Kadmon Pharmaceuticals.
7	Patent CN101237870 B.
8	In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlota... Bioorg Med Chem Lett. 2007 Apr 1;17(7):1996-9.